TMPRSS2-ERG fusion protein activates a transcriptional program that contributes to prostate oncogenesis through upregulation of the expression of some key genes including MYC, EZH2 and SOX9 and repression of NKX3 expression. Here, NKX3-1 is linked to medical procedure.